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ABSTRACT 
 
This protocol describes the isolation of endogenous c-kit-positive (c-kitpos), 
CD45-negative (CD45neg) cardiac stem cells (eCSCs), from whole adult mouse 
and rat hearts. The heart is enzymatically digested via retrograde perfusion 
of the coronary circulation, resulting in rapid and extensive breakdown of 
the whole heart. Next the tissue is mechanically dissociated further and cell 
fractions separated by centrifugation. The c-kitpos CD45neg eCSC population 
is isolated by magnetic activated cell sorting technology and purity and cell 
number assessed by flow cytometry. This process takes approximately 4 
hours for mouse eCSCs or 4.5 hours for rat eCSCs. We also describe how to 
characterise c-kitpos CD45neg eCSCs. The c-kitpos CD45neg eCSCs exhibit the 
defining characteristics of stem cells; being self-renewing, clonogenic and 
multipotent. This protocol also describes how to differentiate eCSCs into 
the three main cardiac lineages: functional, beating cardiomyocytes, 
smooth muscle and endothelial cells. These processes take between 17 and 
20 days.  
 
INTRODUCTION 
 
Although previously considered to be a terminally-differentiated organ, the 
adult mammalian heart has been shown to have the ability to develop new 
cardiomyocytes and microvasculature throughout life 1. It has been further 
demonstrated that the adult mammalian heart contains a population of 
resident endogenous stem and progenitor cells, which have the defining 
characteristics of stem cells: self-renewal, clonogenicity and multipotency 
2. Such cells have been identified in a range of different mammalian 
species, including human by ourselves and other groups 3-23.  
 
Early in this century, the search for the origin of small mono-nucleated 
cardiomyocytes undergoing cytokinesis seen sporadically in normal and 
pathological adult hearts, including human 24, led to the first identification 
of bona fide resident, endogenous cardiac stem/progenitor cells (eCSCs) 
present in the adult myocardium throughout the organisms lifespan which 
are self-renewing, clonogenic and multipotent 2. Shortly after, several 
eCSCs in the adult mammalian heart were identified by different membrane 
markers and transcription factors (which often led to claims of a new stem 
cell type with each new marker used for its identification). Indeed, when 
referring to eCSCs, there are at least seven resident heart populations so far 
identified (mainly according to the single antigen used for their primary 
isolation) in the adult mammalian heart, including the human 25. These are 
c-kitpos eCSCs (that have been also defined as CD34neg, CD45neg, Sca-1pos, 
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Abcg2pos, CD105pos, CD166pos, GATA4pos, NKX2-5pos/neg or low, MEF2Cpos) 2,4-9; 
Sca1pos eCSCs (CD34neg, CD45neg, FLK1neg, ckitpos/neg or low, GATA4pos, NKX2-
5pos/neg or low, MEF2Cpos) 10,11; side population (SP) cells (CD34pos, CD45pos, 
Abcg2pos, Sca1pos, c-kitpos, NKX2-5neg, GATA4neg) 12,13; Cardiosphere-derived 
cells (CD105pos, CD34pos, CD45pos, Abcg2pos, Sca1pos, c-kitlow) 14-16; cardiac-
resident colony-forming unit-fibroblast (cCFU-Fs) (Sca-1pos, PDGFRŞneg, 
CD31neg, c-kitlow, CD45neg, FLK1neg, CD44pos, CD90pos, CD29pos, and CD105pos) 
17; cardiac mesangioblasts (CD31pos, CD34pos, CD44pos, CD45neg, Sca1pos, c-
kitpos) 19; and the Isl-1pos cardiac progenitor cells (CPCs) (CD31neg, Sca1neg, c-
kitneg, GATA4pos, NKX2-5pos) 20,21. The phenotypes and sources of these cell 
populations are summarised in Table 1.  
 
The description of these various eCSC populations led to the paradoxical 
situation whereby the heart, previously described as a non-renewing organ, 
became the organ with the highest number of distinct types of resident 
stem/progenitor cells. However, aside from the Isl-1pos CPCs which are 
direct progeny of a defined embryonic cardiac progenitor cell population 
present in only very small numbers in the adult heart 26 and the epicardial 
stem cells also called cCFU-Fs presumable derivate from the pro-epicardial 
organ17, it is evident just from the significant overlap of the main and 
secondary markers used for their characterization that the different 
eCSC/CPC populations are closely related. So it is not surprising that after 
the early enthusiasm subsided, a consensus is developing that many, if not 
all, different putative adult eCSCs reported so far, likely represent different 
developmental and/or physiological stages of a unique resident stem-
progenitor cell type with multipotent regenerative capacity yet to be 
completely defined 27. Clearly, genetic tracking in genetically-modified 
mice, if properly designed, would be an invaluable tool to try to establish 
the connection among the different eCSC/CPC populations as well as their 
real contribution to heart development, adult myocardial homeostasis and 
disease.  
 
The c-kitpos eCSCs are characterised by expression of c-kit (also known as 
CD117), the receptor for stem cell factor. Although in the myocardium c-kit 
is also expressed by cardiac mast cells, which in contrast to the eCSCs are 
also CD45pos and tryptase positive, removal of the CD45-positive cell lineage 
removes this mast cell population 6. The abundance, distribution and the 
intrinsic regenerative capacity of c-kitpos eCSCs in adult cardiac tissue has 
been recently clarified 4, although their developmental origin has not yet 
been lineage traced (for review see 28,29). It is desirable when isolating 
eCSCs from adult tissue to obtain a cell population of the highest possible 
uniformity in terms of lineage potential, with the cells retaining the ability 
to develop into all four cell lineages required to regenerate the myocardium 
(cardiomyocyte, vascular (endothelial and smooth muscle) and 
mesenchymal). It has been repeatedly demonstrated 2,4-6 that the c-kitpos 
eCSC population are sufficiently primitive to retain this quadri-lineage 
potential, indicating that these are uncommitted cells, i.e. bona fide 
stem/progenitor cells.  
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Here we present effective and highly reproducible protocols for the isolation 
of c-kitpos CD45neg Trypneg eCSCs from the adult whole mouse (C57/BL6J) and 
rat (Wistar) heart, the most commonly utilised small animal models for 
experimental cardiovascular research. These protocols were originally 
developed during the first identification of eCSCs 2. The protocols described 
here are broadly similar for mouse and rat and result in the isolation of 
similar type and number of cells, however there are several procedural 
differences. The key factor in both is the retrograde coronary perfusion 
step, a process initially described by Silver and colleagues in 1983 30, in 
which the coronary arteries are used as a route for buffer and digestive 
enzyme to perfuse through the myocardium. This procedure first removes 
peripheral blood cells and endothelial cells present in the vascular tree and 
subsequently induces prompt digestion of the tissue, thus making it possible 
to isolate separate fractions of the main cardiac cell types, i.e. 
cardiomyocytes, smooth muscle cells, endothelial cells, cardiac fibroblasts 
and eCSCs. Compared to other methods, retrograde coronary perfusion and 
digestion of the whole heart allows the harvest of the highest number of 
eCSCs and it also makes it possible to simultaneously collect rod-shaped 
cardiomyocytes. In addition we describe how to characterise the isolated c-
kitpos CD45neg Trypneg eCSCs and how to induce and characterise their 
differentiated progeny.  
 
Advantages of the protocol 
 
The main advantages of retrograde perfusion of the coronary tree with the 
digestive enzymes are the increased yield and high purity of c-kitpos CD45neg 
Trypneg eCSCs (hereinafter described as eCSCs) that are extracted. The 
isolated eCSCs can be immediately studied further, cryogenically stored, 
characterised, cloned or expanded in vitro. A major difficulty in working 
with eCSCs from adult myocardium is their scarcity and therefore many 
methods for their isolation require an in vitro expansion step. While this 
is effective, depending on the questions addressed, the expansion of the 
eCSCs in the culture environment may represent a confounding variable. 
The methods described here allow a sizeable population of eCSCs to be 
obtained without the need to include an in vitro expansion step.  
 
Experimental Design 
 
This protocol describes the isolation of small cells (of less than 40µm 
diameter) from the mouse (step 1 option A) or rat (step 1 option B) heart, 
with the subsequent removal of CD45-positive haematopoietic lineage cells, 
which remove the blood cell lineage precursors and the mast cells (Tryppos), 
followed by the selection of the cell population positive for c-kit. The 
differences between the two protocols are summarised in Table 2. When 
flow cytometry analysis of the selected eCSC population is planned, it is 
necessary for the mouse and advisable for the rat to collect an aliquot of 
unsorted cardiac small cells for isotype control. Using the rat protocol it is 
also possible to isolate intact, contracting, calcium-resistant, rod-shaped 
cardiomyocytes should this be required. The mouse rod-shaped 
cardiomyocytes are significantly more delicate and many will be killed by 
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the procedure by a leaky membrane that allows an influx of extracellular 
Ca2+. 
 
It is critical when using the retrograde-perfusion method described here 
that the time from death of the animal to successful placing of the heart on 
the perfusion system is minimised. Blood clotting and subsequent occlusion 
of the vessels must be prevented to allow adequate retrograde tissue 
perfusion. Inefficient digestion of the tissue by the perfused enzyme 
solution reduces the quantity and quality of cells recovered. Additionally 
the number of circulatory haematopoietic lineage cells contaminating the 
pool of small cells is increased. Intraperitoneal injection of heparin to the 
animal prior to euthanasia reduces blood clotting and improves perfusion, as 
does rapid cannulation and prompt hanging of the heart on the perfusion 
system.  
 
Given the relatively small number of c-kitpos CD45neg eCSCs that can be 
isolated from a single heart, we recommend that eCSCs are collected from 
no fewer than three-to-six C57/BL6J mice or two Wistar rats at a time. This 
circumvents the fact that if eCSCs are initially seeded at a very low cell 
density, early cell growth is very slow. Once the eCSCs are in culture, 
medium must be replenished every two to three days. Growth can be 
further enhanced by the use of conditioned medium, which enables a quasi-
logarithmic growth rate to be achieved. Passaging of cells when they reach 
~70% confluency prevents overgrowth and cell-to-cell contact, which can 
lead to cell growth inhibition and/or differentiation.  
 
A limitation of the protocol is that we use custom-made specialised 
equipment for the perfusion and digestion of the ex vivo whole heart. 
However, a commercially available version comparable to our system is 
available from AD Instruments (cat. no. PL3508B1-V for mouse, B3-V or B4-V 
for rat) which should allow our system to be reproduced by researchers 
without access to custom-made apparatus. Although we have not tested 
side-to-side the efficacy of the commercial apparatus compared to our 
equipment, if the basic principles of our method are followed they should 
prove to be effective.  
 
Once the c-kitpos CD45neg eCSCs have been isolated, flow cytometry can be 
used to confirm expression of various stem cell surface markers. The cells 
can also be grown in culture. This protocol also describes how to 
characterise the cells for the stem cell properties of clonogenicity, self-
renewal, and multipotency (step 2 options A and B); how to differentiate 
either mouse or rat c-kitpos CD45neg eCSCs into functional, beating 
cardiomyocytes in vitro (step 2 option C); and how to fix and stain cells by 
immunocytochemistry (step 2 options D, E and F).  
 
MATERIALS 
 
REAGENTS 
Common to mouse and rat procedures 
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• Sodium bicarbonate (Sigma S5761) 
• Glutamine (Sigma G7029) 
• 1000ml filter (0.22µm pore, Millipore SCGPT10RE) 
• Collagenase, type II (Worthington 4176) 
CAUTION: Collagenase is an irritant: wear appropriate safety clothing 
and gloves.  
CRITICAL: It is advisable to lot-test collagenase prior to large scale 
experiments, as there is substantial variation in enzyme activity 
between lots.  
• Bovine Serum Albumin (BSA, Sigma A9418) 
• PBS without calcium or magnesium (Invitrogen 14190-136) 
• EDTA (Invitrogen 15575-038) 
• Penicillin-Streptomycin (Invitrogen 15140-122) 
• Fungizone (Invitrogen 15290-018) 
• Gentamicin (Sigma G1397) 
• Heparin sulphate (MP Biomedicals) 
• Sodium pentobarbitone (Euthatal, Merial) 
• 15ml centrifuge tubes (Corning 430791) 
• Cell strainers (40µm pore size, BD biosciences 352340) 
• 50ml Falcon tubes (BD biosciences 352070) 
• Eppendorf 1.5ml tubes (Eppendorf 3810X) 
• MS columns (Miltenyi 130-042-201) 
• Pre-separation filters (Miltenyi 130-041-407) 
• Trypan Blue solution (Sigma T8154) 
• Dulbeccos Minimum Essential Medium-F12-HAMS (Sigma D8437) 
• Insulin-Transferrin-Selenium (Invitrogen 51500-056) 
• Neurobasal medium (Invitrogen 10888-022) 
• B27 supplement (Invitrogen 17504-044) 
• N2 supplement (Invitrogen 17502-048) 
• Embryonic stem cell-qualified foetal bovine serum (Invitrogen 10439-
024) 
• Epidermal growth factor (Peprotech 100-15) 
• Basal fibroblast growth factor (Peprotech 100-18B) 
• Leukemic inhibitory factor (Millipore LIF2010) 
• 6-Well tissue culture plates (BD biosciences 353046) 
• Gelatin (Sigma G1890) 
• PBS (Invitrogen 14040-224) 
 
Only required for mouse eCSC isolation 
• Minimum Essential Medium powder (MEM, Joklik modification Sigma 
M0518) 
• HEPES (Sigma H3375) 
• Taurine (Sigma T7146) 
• C57/BL6J mice (6-8 weeks of age) 
CAUTION: All experiments must be performed in accordance with 
relevant guidelines and regulations.  
• 5/0 suture thread (Fine Science Tools 18020-50) 
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• CD45 mouse MicroBeads (Miltenyi 130-052-301) 
• EasySep CD117 mouse selection cocktail (Stem Cell Technologies 
18757) 
• FITC-conjugated anti-mouse CD45 antibody (Miltenyi 130-091-609) 
• PE-conjugated anti-mouse c-kit antibody (Stem Cell Technologies 
18757C.1) 
 
Only required for rat eCSC isolation 
• Sodium chloride (Sigma S3014) 
• Potassium chloride (Sigma P5405) 
• Magnesium sulphate (Sigma M7506) 
• Potassium phosphate (Sigma P0662) 
• Dextrose (Sigma D9434) 
• Hyaluronidase, type II (Sigma H2126) 
• Dulbeccos Minimum Essential Medium (DMEM, Invitrogen 31885-023) 
• Adult Wistar rats (~250-300g bodyweight) 
CAUTION: All experiments must be performed in accordance with 
relevant guidelines and regulations.  
• 4/0 suture thread (Fine Science Tools 18020-40) 
• Calcium chloride (Sigma C4901) 
• Trypsin, type IX (Sigma T0303): stock solution of 0.3mg/ml 
• DNase, type I (Sigma DN25): stock solution of 0.3mg/ml 
• Cell strainers (100µm pore size, BD biosciences 352360) 
• Optiprep (Sigma D1556) 
• Mouse IgG anti-rat CD45 antibody (Santa Cruz Biotechnology sc53047) 
• Mouse IgG anti-rat CD45 FITC-conjugated antibody (Biolegend 202205) 
• Rabbit IgG anti-rat c-kit antibody (Santa Cruz Biotechnology sc5535) 
• Rat anti-mouse IgG2a+b MicroBeads (Miltenyi 130-047-201) 
• Goat anti-rabbit IgG MicroBeads (Miltenyi 130-048-602) 
• AlexaFluor488-conjugated donkey anti-rabbit antibody (Jackson 711-
545-152-JIR) 
• AlexaFluor 594-conjugated donkey anti-rabbit antibody (Jackson 711-
585-152-JIR) 
 
For characterisation of cells (mouse or rat) 
• MEM (alpha modification, Sigma M0894) 
• Foetal calf serum (Invitrogen 10106-151) 
• Oxytocin acetate (Sigma O6379) 
• Ascorbic acid (Sigma A4403) 
• Dexamethasone (Sigma D4902) 
• Beta-glycerol phosphate (Sigma G9891) 
• Penicillin/Streptomycin (Invitrogen 15140-122) 
• Gentamicin (Sigma G1397) 
• Fungizone (Invitrogen 15290-018) 
• TGF-ş1 (Peprotech 100-21) 
• BMP-2 (Peprotech 120-02) 
• BMP-4 (Peprotech 120-05ET) 
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• Dkk-1 (R and D systems 4010-DK-010) 
• Wnt5a (R and D systems 645-WN-010) 
• PBS without calcium or magnesium (Invitrogen 14190-136) 
• EDTA (Invitrogen 15575-038) 
• Poly-prep slides (Sigma P0425-72) 
• Shandon Cytofunnels (Thermo-Fisher SDA78710005) 
• ImmEdge pen (Vector laboratories H-4000) 
• Shandon Cell-Fixx (Thermo-Fisher 6768326) 
• CAUTION: Toxic chemical: wear appropriate safety clothing and 
gloves.  
• Laminin (Sigma L2020) 
• DMEM (Invitrogen 31885-023) 
• 4-Well chamber slides (BD biosciences 354114) 
• 16% Formaldehyde solution (TAAB F017/3) 
• CAUTION: Toxic chemical: wear appropriate safety clothing and 
gloves.  
• PBS (Invitrogen 14040-224) 
• Tween 20 (BioRad 170-6531) 
• Triton-X (Sigma T8787) 
• Donkey serum (Sigma D9663) 
• DAPI (Sigma D9542) 
• CAUTION: Toxic chemical: wear appropriate safety clothing and 
gloves.  
• Vectashield (Vector laboratories H1000) 
• Anti-mouse Sca-1-FITC conjugated antibody (Miltenyi 130-098-034) 
• Anti-mouse CD31-FITC conjugated antibody (Miltenyi 130-100-003) 
• Anti-mouse CD34-FITC conjugated antibody (BD 560238) 
• Anti-mouse CD90-PE conjugated antibody (Abcam Clone G7, ab24904) 
• Anti-mouse CD105-PE conjugated antibody (Miltenyi 130-098-018) 
• Anti-mouse CD140a-PE conjugated antibody (Miltenyi 130-096-271) 
• Anti-mouse CD166-PE conjugated antibody (eBioscience 12-1661-81) 
• Anti-mouse CD45 FITC-conjugated antibody (Miltenyi 130-091-609) 
• Mouse IgG1 PE Isotype control (Abcam ab81200) 
• Mouse IgG2a FITC Isotype control (Abcam ab81197)  
• Anti-mouse CD117-PE conjugated antibody (Miltenyi 130-091-730) 
• Anti-mouse CD45-PE conjugated antibody (Miltenyi 130-091-610) 
• Anti-tryptase antibody (Santa Cruz Biotechnology sc32473) 
• Goat polyclonal anti-c-kit antibody (R and D systems AF1356) 
• Mouse IgM anti-Ş-sarcomeric actin antibody (Sigma A2127) 
• Mouse IgG anti-smooth muscle actin antibody (Sigma A2547) 
• Rabbit polyclonal anti-von Willebrand factor antibody (Dako A0082) 
• Mouse monoclonal anti-Ş-actinin sarcomeric antibody (Sigma Clone 
EA-53, A7811) 
• Rabbit polyclonal anti-Connexin 43 antibody (Sigma C6219) 
• AlexaFluor 488 donkey anti-goat antibody (Jackson 705-545-147-JIR) 
• AlexaFluor 594 donkey anti-mouse IgM antibody (Jackson 715-585-
140-JIR) 
9 
 
• AlexaFluor 594 donkey anti-mouse IgG antibody (Jackson 715-585-
151-JIR) 
• AlexaFluor 488 donkey anti-rabbit antibody (Jackson 711-545-152-JIR) 
• AlexaFluor 594 donkey anti-rabbit antibody (Jackson 711-585-152-JIR) 
• Alexa Fluor 488 donkey anti-mouse IgG antibody (Jackson 715-545-
150-JIR) 
• RNeasy mini kit (Qiagen 74104) 
• First Strand reverse transcription kit (Applied Biosystems 4368814) 
• iQ SYBR green supermix (BioRad 170-8882) 
• Primers (Sigma, custom-made) 
• RNase, DNase-free water (Sigma W4502) 
 
EQUIPMENT 
Common to mouse and rat procedures 
• Retrograde perfusion system, comprising  
Fluid pump (Cole-Parmer), Water heater and circulator 
(Thermo-Fisher), Glass fluid warming system (custom-made or 
PL3508B1-V, B3-V or B4-V from AD instruments) and Tubing 
(96410-16, Cole-Parmer) 
• Eppendorf centrifuge (Eppendorf 5810 R) 
• Eppendorf centrifuge (Eppendorf 5418) 
• OctoMACS magnet and stand (Miltenyi) 
• Haemocytometer (Hausser scientific) 
• FACSCalibur II flow cytometer (Becton Dickinson) 
• Humidified 37ºC, 5% CO2 sterile incubator (HealForce HF90) 
 
Only required for mouse eCSC isolation 
• Cannulae for the Retrograde perfusion system: 1st cannula BB31695-
PE/3, Scientific Commodities; 2nd cannula BB311-19, 19 gauge, 
Scientific Commodities; 3rd cannula  06409-14; Cole Parmer 
• Fine dissecting tools, including Vannas scissors (Fine Science Tools) 
• EasySep magnet (Stem Cell Technologies) 
 
Only required for rat eCSC isolation 
• Cannulae for the retrograde perfusion system: 1/4-28 Threaded 
Adapter (5809-12, Ace Glass) inserted into L/S 16 tubing (Cole-
Parmer, 96410-16) 
• Dissecting tools (Fine Science Tools) 
 
Only required if preparing cells for immunocytochemistry by cytospin 
• Cytospin 4 (Thermo-Fisher) 
 
Only required if analysing cells by real-time qPCR 
• Nanodrop (Thermo-Fisher) 
• iCycler (BioRad) 
• MyIQ (BioRad) 
 
REAGENT SET-UP 
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Incubation Medium for sorting mouse or rat cells 
PBS without calcium or magnesium containing Bovine Serum Albumin 
(5mg/ml), EDTA (2mM), Penicillin-Streptomycin (1% vol/vol), Fungizone 
(0.1% vol/vol) and Gentamicin (0.1% vol/vol) 
 
Prepare 50ml incubation medium, sterilise through a 0.22µm pore filter into 
a sterile container and keep at 4ºC up to three weeks before the procedure.   
 
Basic Buffer for isolating mouse cells 
MEM (Joklik modification) 
Sodium bicarbonate (2g/l) 
HEPES (0.7mg/ml) 
Taurine (1.25mg/ml) 
Glutamine (0.3mg/ml) 
 
Prepare 1000ml Basic Buffer, pH to 7.3 and sterilise through a 0.22µm pore 
filter into a sterile container. This may be prepared up to three days before 
tissue collection if kept sterile at 4ºC.   
 
Collagenase Buffer for isolating mouse cells 
Collagenase powder at a final concentration of 250U/ml in Basic Buffer.  
 
Prepare 200ml collagenase solution and filter-sterilise as previously: this 
volume is sufficient to perfuse three hearts or six if the collagenase is 
collected after perfusion and re-cycled.  
CRITICAL: This must be prepared shortly before tissue collection and the 
solution kept chilled prior to use to minimise enzyme degradation. 
 
BSA Incubation Buffer for isolating mouse cells 
BSA 5mg/ml in Basic Buffer 
 
Prepare 200ml BSA incubation buffer and filter-sterilise as previously: this 
volume is sufficient to perfuse three hearts or six if the solution is collected 
and re-cycled. This solution should be prepared the day before tissue 
collection and stored at 4ºC prior to use.  
 
Mouse eCSC Growth Medium 
(as established in 4) 
45% of the following: 
 Dulbeccos Minimum Essential Medium-F12-HAMS 
 Insulin-Transferrin-Selenium (1% vol/vol) 
 Penicillin-Streptomycin (1% vol/vol) 
 Fungizone (0.1% vol/vol) 
 Gentamicin (0.1% vol/vol) 
45% of the following: 
 Neurobasal medium  (supplement with 37mg L-glutamine per 500ml) 
 B27 supplement (2% vol/vol) 
 N2 supplement (1% vol/vol) 
10% vol/vol Embryonic stem cell-qualified foetal bovine serum 
Epidermal growth factor (20ng/ml) 
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Basal fibroblast growth factor (10ng/ml) 
Leukemic inhibitory factor (10ng/ml) 
 
Prepare 200ml growth medium, sterilise through a 0.22µm pore filter into a 
sterile container and keep at 4ºC up to three weeks before the procedure.   
 
Krebs-Henseleit (K-H) buffer for isolating rat cells  
Sodium chloride: final concentration of 6.896g/l 
Potassium chloride: final concentration of 0.35g/l 
Magnesium sulphate: final concentration of 0.144g/l 
Potassium phosphate: final concentration of 0.1635g/l 
Sodium bicarbonate: final concentration of 2.1g/l 
Dextrose: final concentration of 2.16g/l 
 
Prepare 1000ml buffer, adding 50ml of concentrated stock solutions of 
sodium chloride, potassium chloride, magnesium sulphate, potassium 
phosphate and sodium bicarbonate to ddH2O to a total volume of 1000ml, 
followed by addition of 2.16g of dextrose and filter-sterilise through a 
0.22µm pore filter into a sterile container. This may be prepared and kept 
at 4ºC up to one week before the procedure.  
 
Wash medium for isolating rat cells 
25ml K-H buffer 
25ml DMEM 
250µl Penicillin/Streptomycin 
 
Prepare wash medium, sterilise through a 0.22µm pore filter into a sterile 
container and keep at 4ºC up to one week before the procedure.  
 
Collagenase and Hyaluronidase solution for isolating rat cells 
150ml K-H buffer 
Collagenase, type II: final concentration of 128U/ml 
Hyaluronidase, type II: final concentration of 200U/ml 
 
Prepare 150ml collagenase and hyaluronidase solution and sterilise through 
a 0.22µm pore filter into a sterile container. The volume is sufficient for 
perfusion of three rat hearts, but has to be collected and re-used over this 
time.  
CRITICAL: This must be prepared shortly before tissue collection and the 
solution kept chilled prior to use to minimise enzyme degradation.  
 
Rat eCSC Growth Medium 
(as established in 4,31,32) 
45% of the following: 
 Dulbeccos Minimum Essential Medium-F12-HAMS 
 Insulin-Transferrin-Selenium (1% vol/vol) 
 Epidermal growth factor (final medium concentration: 20ng/ml) 
 Basal fibroblast growth factor (final medium concentration: 10ng/ml) 
 Leukemic inhibitory factor (final medium concentration: 10ng/ml) 
45% of the following: 
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 Neurobasal medium (supplement with 37mg L-glutamine per 500ml) 
 B27 supplement (2% vol/vol) 
 N2 supplement (1% vol/vol) 
10% vol/vol Embryonic stem cell-qualified foetal calf serum  
Penicillin-Streptomycin (1% vol/vol) 
Fungizone (0.1% vol/vol) 
Gentamicin (0.1% vol/vol) 
 
Prepare 200ml growth medium, sterilise through a 0.22µm pore filter into a 
sterile container and keep at 4ºC up to three weeks before the procedure.  
 
Incubation Medium for Cytospin or Flow Cytometry 
PBS without calcium or magnesium  
Bovine Serum Albumin (5mg/ml) 
EDTA (2mM) 
Penicillin-Streptomycin (1% vol/vol) 
Fungizone (0.1% vol/vol) 
Gentamicin (0.1% vol/vol) 
 
Prepare 50ml incubation medium, sterilise through a 0.22µm pore filter into 
a sterile container and keep at 4ºC up to three weeks before the procedure.  
 
Cardiomyogenic differentiation medium 
MEM (alpha modification) 
Foetal calf serum: final concentration of 2% vol/vol 
Oxytocin acetate: final concentration of 100nM 
Ascorbic acid: final concentration of 50µg/ml 
Dexamethasone: final concentration of 1µM 
Beta-glycerol phosphate: final concentration of 10mM 
Penicillin/Streptomycin: final concentration of 1% vol/vol 
Gentamicin: final concentration of 0.1% vol/vol 
Fungizone: final concentration of 0.1% vol/vol 
TGF-ş1 (5ng/ml, days 1-4) 
BMP-2 (10ng/ml, days 1-4) 
BMP-4 (10ng/ml, days 1-4) 
Dkk-1 (150ng/ml, days 5-14) 
 
Prepare 200ml differentiation medium, sterilise through a 0.22µm pore 
filter into a sterile container and keep light-shielded at 4ºC up to three 
weeks before the procedure.  
 
EQUIPMENT SET-UP 
Perfusion system for mouse and rat heart perfusion 
Our system consists of: flexible tubing run through a fluid pump, drawing up 
fluid (e.g. Basic Buffer) and propelling this through our custom-made glass 
tubing system for fluid heating, in which the fluid is heated to 37ºC by 
passing through coils inside chambers filled with an external water supply 
warmed to 37ºC (this external water temperature being regulated by the 
water bath). The warmed fluid then drips out via the tubing, with the 
terminal tube of a diameter which allows firm attachment of the cannulae. 
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See Figure 1 for a diagram of our system. Alternatively AD Instruments sell a 
perfusion system (cat. no. PL3508B1-V for mouse, B3-V or B4-V for rat). 
 
PROCEDURE 
 
1 For isolation of mouse eCSCs follow option A. For the isolation of rat 
eCSCs follow option B. See Table 2 for a summary of the differences 
between the mouse and rat protocols. See Table 3 for antibody 
concentrations.   
 
(A) Isolating c-kitpos eCSCs from the mouse heart 
 
(i) Rinse perfusion system with 70% vol/vol ethanol for 10 minutes to 
sterilise and re-rinse with ddH2O for 10 minutes to remove all traces of 
ethanol prior to use. Commence running the Basic Buffer through the 
system.  
 
(ii) Inject 1000IU/kg heparin sulphate intraperitoneally into 6-week-old 
C57/BL6J mice and after ~10 minutes sacrifice the animal (we use an 
overdose of sodium pentobarbitone). Sterilise the anterior surface and 
dissect as follows: open skin on abdomen with midline incision and retract 
fur and skin; open abdominal cavity and make lateral incisions to inferior 
edge of ribcage; make vertical cuts along lateral border of ribcage then 
transversely across diaphragm to expose heart.  
 
CAUTION: All experiments on mice must be performed in accordance with 
relevant guidelines and regulations.  
 
CRITICAL STEP: If intending to isolate RNA directly from isolated eCSCs, it is 
advisable to omit heparin administration: in this instance rapid cannulation 
is even more vital.  
 
CRITICAL STEP: This and the following two steps must be carried out 
rapidly: depending on the number of operators and facilities available, it 
may be necessary to sacrifice mice one at a time. If the time elapsed from 
sacrifice to perfusion is longer than 10 minutes, the yield and quality of the 
isolated eCSCs will be severely negatively affected.  
 
(iii) Remove ribcage flap at superior end and discard; remove thymus with 
forceps to expose arch of aorta; thread an 8cm length of 5/0 suture behind 
the ascending aorta using fine forceps; hold innominate artery in place with 
fine forceps and cut part-way through aorta immediately distal to origin of 
innominate with Vannas scissors, producing opening over ascending aorta; 
insert fine-bore cannula (19 gauge) into opening and advance gently into 
ascending aorta, being sure to stop before passing through the aortic valve 
and entering the ventricular cavity; tie in place with 5/0 suture; grasp aorta 
over cannula tie with forceps and dissect heart out from thoracic cavity 
fully (see Figure 2a-f).  
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(iv) Place cannula into aperture of retrograde perfusion system (Figure 2g) 
with pump running at 10.2ml/min: equating to 3.4ml/min per cannula, and 
perfuse heart with Basic Buffer for 5 minutes or until all blood has been 
removed. If necessary, pierce apex with 25-gauge needle to allow pooled 
blood to be removed. Also check for leaks between the cannula and the 
aortic root. Re-do or tighten the suture connection if needed. 
 
(v) Once blood is removed, perfuse with collagenase solution for 10-12 
minutes to digest tissue. The heart should enlarge slightly and tissue will 
become pale and flaccid if perfusion is successful (Figure 2h).  
 
(vi) Next perfuse heart with BSA solution for 5 minutes to stop collagenase 
reaction and prevent over-digestion. Depending on perfusion apparatus, it 
should be possible to perfuse 3-4 hearts simultaneously.  
 
(vii) Once all hearts have been fully perfused, collect hearts and transfer to 
25ml conical flask (3 hearts per flask, 5-10ml of BSA solution per flask) and 
chop into ~1-2mm pieces with fine sterile scissors.  
 
(viii) Run suspension up and down through transfer pipette ten times to 
further break up tissue fragments.  
 
(ix) Transfer suspension into 15ml centrifuge tube and centrifuge at 300g, 
brake 3, for 1 minute at room temperature (20-22ºC) to separate suspension 
into myocyte and small cell fractions. If recovery and study of the 
cardiomyocyte fraction is desired, the cells within the pellet can be 
retrieved at this stage as previously described4.  
 
(x) Retain supernatant (containing small cell fraction) and pass through 
40µm cell strainer into 50ml centrifuges tube. Next add BSA solution to give 
a total volume in the tube of 30ml per tube.  
 
(xi) Centrifuge tube at 330g, brake 7 for 7 minutes at room temperature to 
pellet small cell fraction, discard supernatant and re-suspend pellet in 1ml 
incubation medium. Count an aliquot of the cells using a haemocytometer, 
prior to proceeding to the next steps (cell selection).  
 
(xii) If desired, analyse the isolated cells (the cardiac small cell fraction) by 
flow cytometry to identify the percentage of cardiac small cells which 
express different stem cell surface markers of interest. We monitor 
expression of CD45 and c-kit (Figure 3a,b). Alternatively, proceed directly 
to the next step to purify the c-kitpos CD45neg eCSCs via magnetic cell sorting 
(steps A (xiii)-(xv)). If intending flow cytometry analysis of the selected 
eCSC population, retain an aliquot of unsorted cardiac small cells for the 
isotype control (Supplementary Figure 1a).  
 
(xiii) Label the CD45-positive cells using the Miltenyi anti-mouse CD45 
MicroBead kit, according to manufacturers instructions. In brief, first re-
suspend the cell fraction in incubation medium with the MicroBeads (volume 
of 20µl MicroBeads per 107 cells, cell number as ascertained in step A (xiv)) 
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and incubate for 15 minutes at 4ºC. Wash in incubation medium prior to 
centrifugation and re-suspension in incubation medium. Finally run the cell 
suspension through a MS magnetic sorting column placed in an OctoMACS 
magnet attached to its stand (Miltenyi), with a 30µm pre-separation filter 
(Miltenyi) fitted above the column. Run the suspension through the system 
drop-wise, followed by three washes with 500µl incubation medium to rinse 
through all unbound cells. Proceed to the next step to further purify the 
unlabelled cell fraction (CD45-negative fraction).  Retain the positively-
labelled cells for later flow cytometric analysis. 
 
(xiv) Use the CD45-negative fraction (from step A (xiii)) with the StemCell 
Technologies EasySep anti-mouse CD117 kit to label the CD117-positive (c-
kitpos) fraction, according to manufacturers instructions. In brief, first label 
the CD45-negative cell fraction with an anti-c-kit antibody conjugated to 
phycoerythrin (PE) for 15 minutes, followed by an anti-PE/anti-dextran 
secondary antibody complex for 15 minutes and finally with magnetic 
dextran-iron nanoparticles to tag the secondary antibody for 10 minutes (all 
incubations at room temperature). Following these incubations rinse the 
cells with 5ml of incubation medium and place inside the EasySep magnet 
for 5 minutes at room temperature. Empty the tube while still within the 
magnet, thus retaining all labelled cells. Rinse the cells and empty the 
magnet a total of five times. Finally remove the tube from the magnet. 
 
(xv) Count the cells remaining in the tube (the c-kitpos CD45neg cell fraction) 
using a haemocytometer. Usually ~30,000 c-kitpos CD45neg cells are obtained 
from each mouse heart (~200 eCSCs per milligram of tissue). Use Trypan 
blue exclusion to ensure cell viability is >95%. At this stage flow cytometry 
analysis of the cell population purity can be carried out if desired (Figures 4 
and 5). To proceed direct to characterisation, go straight to step 2. 
 
(xvi) If in vitro culture of the cells is required, re-suspend cells in mouse 
eCSC growth medium and plate onto vessels pre-coated with 1.5% wt/vol 
gelatin and incubate at 37ºC for 24 hours (see Table 4 for cell plating 
density; we usually plate the cells from six hearts onto three wells of a 6-
well plate at this stage). If cell culture is not required, the procedure can 
proceed directly to characterisation (step 2).  
 
(xvii) Replace medium on cells after the first 24 hours in culture and then 
every 2-3 days. Passage the cells using standard trypsin passage when they 
reach ~70% confluence. The eCSCs can be maintained in vitro for at least 30 
passages without loss of stem cell properties (see Anticipated Results 
section). Cell growth may be assisted by using medium previously 
conditioned by eCSCs in vitro, up to 50% of the total medium volume (mixed 
with fresh medium).  
 
(B) Isolating c-kitpos eCSCs from the rat heart 
 
(i) Rinse perfusion system with 70% vol/vol ethanol for 10 minutes to 
sterilise, and re-rinse with ddH2O for 10 minutes to remove all traces of 
ethanol prior to use. Commence running the K-H buffer through the system.  
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(ii) Inject 1000IU/kg heparin sulphate intraperitoneally into 8-week old 
Wistar rats, then after ~10 minutes sacrifice the animal and dissect as 
follows: open skin on abdomen with midline incision and retract fur and 
skin; open abdominal cavity and make lateral incisions to inferior edge of 
ribcage; make vertical cuts along lateral border of ribcage then transversely 
across diaphragm to expose heart.  
 
CAUTION: All experiments on rats must be performed in accordance with 
relevant guidelines and regulations.  
 
CRITICAL STEP: If intending to isolate RNA directly from isolated eCSCs, it is 
advisable to omit heparin administration: in this instance rapid cannulation 
is even more vital.  
 
CRITICAL STEP: This and the following two steps must be carried out 
rapidly: as for mice, it may be necessary to sacrifice rats one at a time. If 
the time elapsed from sacrifice to perfusion is longer than 10 minutes, the 
yield and quality of the isolated eCSCs will be severely negatively affected.  
 
(iii) Remove ribcage flap at superior end and discard; remove thymus with 
forceps to expose arch of aorta and dissect out heart fully, ensuring that at 
least 3mm of aorta stump is removed along with the heart.  
 
(iv) Lift heart using forceps placed on walls of aorta stump, then lift onto 
cannula, with aortic walls around the cannula end (do not enter the 
ventricular cavity). Secure and tie in place using 4/0 suture thread (see 
Figure 6a-c) and perfuse heart (pump running at 20.4rpm: equating to 
6.8ml/min per cannula) with K-H buffer for 5 minutes or until all blood has 
been removed. If necessary, pierce apex with 21-gauge needle to allow 
pooled blood to be removed. As for the mouse, check for leaks between the 
cannula and the aortic root. Re-do or tighten the suture connection if 
needed. 
 
(v) While K-H buffer rinsing is ongoing, with great care place forceps inside 
heart chambers via openings of great vessels and open and close slightly to 
dislodge pooled blood and aid perfusion.  
 
(vi) Once all blood is removed, perfuse with collagenase/hyaluronidase 
solution for 15 minutes to digest tissue. The heart should enlarge slightly 
and tissue will become pale and flaccid if perfusion is successful. As with 
the mouse, it should be possible depending on perfusion apparatus to 
perfuse three hearts simultaneously (Figure 6d).  
 
(vii) Remove heart(s) from cannula and place in sterile container with lid 
with 15ml of collagenase/hyaluronidase solution and cut into pieces (~5mm 
in size).  
 
(viii) Add 15µl of 1M calcium chloride (only if interested in collecting the 
cardiomyocytes), trypsin (to a final concentration of 20µg/ml) and DNase (to 
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a final concentration of 20µg/ml) to the 15ml collagenase/hyaluronidase 
tissue suspension.  
 
(ix) Place tissue suspension in shaking water bath at 150rpm at 37ºC for 40 
minutes, to dissociate tissue.  
 
(x) Pipette suspension up and down through a 25ml pipette ten times to 
fully break up tissue fragments and run suspension through a cell strainer 
(100µm filter pore size) into a 50ml centrifuge tube. Rinse suspension 
container with 40ml of wash medium and add solution (through the cell 
strainer) to the cell suspension and a second 50ml centrifuge tube, until 
there are equal volumes in each tube.  
 
(xi) Centrifuge both tubes at 50g, brake 3 for 3 minutes at room 
temperature, collecting supernatant (containing small cell fraction), and 
run through cell strainer (40µm filter pore size) into two new centrifuge 
tubes. At this step the pellet of cardiomyocytes can be re-suspended and 
run through a BSA gradient to separate viable rod-shaped cardiomyocytes if 
required, as previously described 32.  
 
(xii) Centrifuge at 400g, brake 7 for 7 minutes at room temperature and 
discard supernatant, combining both small cell pellets in incubation 
medium.  
 
(xiii) Remove subcellular debris by applying the cell suspension carefully 
above 8ml of Optiprep/DMEM mixture (with a density of 1.09/ml) and 
centrifuge at 800g for 15 minutes at room temperature. Intact cells (cardiac 
small cell fraction) should pellet at the bottom of the Optiprep/DMEM layer. 
Count cells using a haemocytometer.  
 
(xiv) As with the mouse, if desired analyse the cardiac small cell fraction 
using flow cytometry, to identify the percentage of cells which express 
different stem cell surface markers of interest. In particular, we examine 
the expression of CD45 and c-kit (Figure 7a,b). Alternatively, proceed 
directly to the next step to purify the c-kitpos CD45neg eCSCs by magnetic cell 
sorting (steps B (xv) to (xviii)). If intending flow cytometry analysis of the 
selected eCSC population, retain an aliquot of unsorted cardiac small cells 
for the isotype control (Supplementary Figure 1c). 
 
(xv) Incubate cardiac small cells (from step xiv) with anti-rat CD45 antibody 
(Santa Cruz), applied at a concentration of 1µg per million cells in 
incubation medium (to a total volume of 1ml) for 15 minutes at 4ºC and 
centrifuge at 300g, brake 7 for 7 minutes at 4ºC, discarding supernatant. At 
this point mast cells can be identified by immunostaining for tryptase 
(Figure 7c), if desired. 
 
(xvi) Incubate cells with Miltenyi rat anti-mouse IgG MicroBeads, according 
to manufacturers instructions. In brief, label the re-suspended cell fraction 
in incubation medium with the MicroBeads for 15 minutes at 4ºC, wash in 
incubation medium, and then pellet by centrifugation and re-suspend in 
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incubation medium. Run the cell suspension drop-wise through a magnetic 
sorting MS column placed in an OctoMACS magnet attached to its stand 
(Miltenyi), with a 30µm pre-separation filter (Miltenyi) fitted above the 
column. Wash the column three times with 500µl incubation medium to 
rinse through all unbound cells. Collect the unlabelled cell fraction and 
retain the positively-labelled cells for later flow cytometric analysis. 
 
(xvii) Incubate the unlabelled cell fraction from step (xvi) (CD45-negative 
cells) with anti-c-kit antibody (Santa Cruz) for 30 minutes in incubation 
medium (to a total volume of 1ml) at 4ºC, centrifuge at 300g, brake 7 for 7 
minutes at 4ºC, discarding supernatant.  
 
(xviii) Incubate cells with Miltenyi goat anti-rabbit MicroBeads and perform 
c-kit positive selection with Miltenyi MS columns, OctoMACS and pre-
separation filters as described in step xvi, but this time collecting the 
positively labelled cell fraction by removing the magnetic column from 
OctoMACS apparatus and flushing with 1ml incubation medium. Retain the 
negatively-labelled cells for later flow cytometric analysis.  
 
(xix) Count the c-kitpos CD45neg cell fraction using a haemocytometer. We 
usually obtain ~150,000 c-kitpos CD45neg positive cells from each rat heart 
(~170 eCSCs per milligram of tissue). Use Trypan blue exclusion to ensure 
cell viability is >95%. At this stage, flow cytometry analysis of the cell 
population purity can be carried out (Figures 8 and 9). 
 
(xx) If in vitro culture of the cells is required, re-suspend cells in rat eCSC 
growth medium and plate on plates pre-coated with 1.5% wt/vol gelatin 
(see Table 4 for cell plating density). If cell culture is not required, the 
procedure can proceed directly to characterisation (step 2). 
 
(xxi) Allow cells to multiply, feeding after 24 hours in culture and then 
every 2-3 days, passaging when cells reach ~70% confluence. As for mouse 
eCSCs, cell growth may be assisted by using medium previously conditioned 
by eCSCs in vitro, up to 50% of the total medium volume (mixed with fresh 
medium). 
 
Characterisation of eCSCs  
 
2 eCSCs can be further studied in a number of ways. Individual eCSCs can be 
characterised functionally by clonogenic assay (option A), used for the 
CardioStem sphere formation assay (option B) or CardioStem spheres used to 
commence the cardiomyogenic beating assay (option C). To perform 
immunocytochemistry before or in the absence of functional 
characterisation on either individual eCSCs or CardioStem spheres, first fix 
cells using a cytospin (option D). To perform immunocytochemistry after 
functional characterisation on either individual eCSCs or CardioStem 
spheres, culture and fix in a slide (option E). Following options D or E, 
immunocytochemistry (option F) can be performed on either individual 
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eCSCs or CardioStem spheres. Individual eCSCs, CardioStem Spheres or 
differentiated progeny can be analysed using real-time qPCR (option G).  
 
(A) Clonogenicity assay 
 
(i) Place  single c-kitpos CD45neg cells into each well of a 96-well 1.5% wt/vol 
gelatin coated Terasaki plates with 100µl of eCSC growth medium per well.   
 
(ii) Incubate the cells and add an extra 20µl of growth medium to each well 
every three days until 9 days after plating. 
 
(iii) On days 3, 6 and 9 count the number of clones generated in each plate 
and calculate the percentage of single cells plated per plate that have 
generated clonal colonies. 
 
(B) CardioStem Sphere formation  
 
CRITICAL Cells must be established in culture for at least one passage (have 
gone through steps A (xvi-xvii) for mouse cells and steps B (xx-xxi) for rat 
cells) prior to commencing this assay. 
 
(i) Grow ~40,000 eCSCs in suspension in 5ml of LIF-deprived eCSC growth 
medium in a 10cm bacteriological dish (to minimise eCSC surface 
adherence). 
 
(ii) Add 2ml of LIF-deprived eCSC growth medium to each plate every 2-3 
days. 
 
(iii) Count the number of CardioStem Spheres per plate and express as a 
percentage relative to the number of eCSCs plated. The first CardioStem 
Spheres have usually formed by 3-4 days.  
 
(C) Cardiomyogenic beating assay 
 
(i) Incubate cloned c-kitpos CD45neg eCSCs (clones obtained using option A) 
with 100nM Oxytocin for 72 hours. 
 
(ii) Transfer ~40,000 eCSCs to 5ml of LIF deprived eCSC growth medium in a 
10cm bacteriological dish (to minimise eCSC surface adherence) and 
incubate cells. 
 
(iii) Add 2ml of LIF deprived eCSC growth medium to each plate every 2-3 
days until CardioStem spheres form (usually within 4 days). 
 
(iv) Transfer CardioStem Spheres to laminin (1µg/ml) coated dishes or 
chamber slides (for later immunostaining) and incubate with cardiomyogenic 
differentiation medium. 
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(v) Specific growth factors are added at specified time points, for up to 14 
days (days 1 to 4: 10ng/ml BMP-2, 10ng/ml BMP-4, 5ng/ml TGF-ş1; days 5 to 
14: 150ng/ml Dkk-1). 
 
(vi) Count the number of beating CardioStem Spheres in each dish. Calculate 
the percentage of beating CardioStem Spheres relative to the total number 
of CardioStem Spheres/clusters in each dish. 
 
(D) Preparation of cells for immunocytochemistry using a Cytospin. 
 
(i) Collect cells by centrifugation at 300g for 5 minutes (using eCSCs either 
freshly isolated or from culture) and resuspend in incubation medium at a 
cell density of 200,000 cells/ml.  
 
(ii) Pre-label the Polyprep slides in pencil (do not use ink as slides are rinsed 
in ethanol subsequently), place in Cytofunnels and load into Cytospin 4.  
 
(iii) Load 200µl of cell suspension into each cuvette and spin at 800rpm for 3 
minutes at MEDIUM acceleration.  
 
(iv)  Extract slide from Cytofunnel apparatus, circle cell spots with 
ImmEdge pen and fix with Cell-Fixx spray.  
 
(v) Allow slides to air dry for 30 minutes and store until required for 
immunocytochemistry.  
PAUSEPOINT: Slides are now fixed and wax-coated, so can be stored at 
room temperature for extended periods (up to at least two years if 
necessary).  
 
(vi) Remove wax coating from slides by immersing in 95% vol/vol ethanol 
solution for 15 minutes. Proceed with immunocytochemistry procedure 
(option F).  
 
(E) Preparation of cells for immunocytochemistry using chamber slide 
culture. 
 
(i) Coat 2- or 4-well chamber slides with laminin dissolved in DMEM (to a 
final concentration of 1µg/ml) for 1-2 hours. Rinse in PBS immediately prior 
to proceeding to step (ii).  
 
(ii) Plate cells or CardioStem Spheres (from option B step iii; 2 to 4 spheres 
per well). Incubate cells in LIF deprived eCSC growth medium for 7 days to 
assay multipotency.  Alternatively incubate up to 14 days in cardiomyogenic 
differentiation medium to assay beating cells. Replace with fresh medium 
and growth factors for both assays every 3 days. 
 
(iii) At desired end-point of experiment, rinse cells once with PBS and fix by 
applying 4% vol/vol formaldehyde (vol/vol in PBS) for 20 minutes on ice. 
 
(iv) Aspirate formaldehyde and proceed to option F (immunocytochemistry). 
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PAUSE POINT: Fixed cells may be rinsed three times in PBS and stored at 
4ºC for up to four days before commencing option F 
(immunocytochemistry).  
 
(F) Immunocytochemistry. 
 
(i) Wash slides three times in 0.1% vol/vol Tween in PBS for 5 minutes on 
orbital shaker.  
 
(ii) Block non-specific binding sites on cells with 10% vol/vol donkey serum 
at room temperature (all secondary antibodies used are raised in donkey).  
 
(iii) Incubate overnight in a humidified chamber with primary antibody 
diluted in 0.1% vol/vol Tween in PBS at 4ºC.  
 
(iv) Wash slides three times in 0.1% vol/vol Tween in PBS for 5 minutes each 
on orbital shaker.  
 
(v) Incubate with secondary antibody in light-shielded, humidified chamber 
for 1 hour at 37ºC.  
 
(vi) Wash slides three times in 0.1% vol/vol Tween in PBS for 5 minutes each 
on orbital shaker (shielded from light).  
 
(vii) Incubate with 4',6-diamidino-2-phenylindole (DAPI, 1ng/ml in PBS) for 
14 minutes at room temperature (shielded from light).  
 
(viii) Wash slides three times in PBS for 5 minutes each on orbital shaker.  
 
(ix) Mount slides in Vectashield (for chamber slides, chamber wells must be 
removed immediately prior to this step). 
 
(x) Proceed to confocal microscopy imaging.  
 
(G) Real-time quantitative PCR 
 
(i) Collect cells in pellet (at least 500,000 cells or 5,000 CardioStem 
Spheres) and wash once with PBS then centrifuge at 300g for 5 minutes, 
aspirating supernatant.  
 
(ii) Isolate RNA using RNeasy mini kit (Qiagen): briefly, cells are lysed in 
700µl RLT lysis buffer then passed through a QIAshredder column by 
centrifuge at 8000g for 15 seconds; the resultant lysate is mixed with an 
equal volume of 70% molecular biology-grade ethanol and bound to an 
RNeasy elution column by centrifuge at 8000g for 15 seconds. Remove any 
residual genomic DNA with DNase (BioRad), then wash the column and elute 
the RNA fraction in 40µl of RNase, DNase-free water at 8000g for 1 minute.  
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(iii) Check RNA quality by analysing with a Nanodrop spectrophotometer 
(Thermo Fisher). Proceed only if RNA purity sufficient (260nm/280nm ratio 
1.9-2.1; 260nm/230nm ratio >1.7).  
PAUSE POINT: At this stage, eluted RNA can be stored at -80ºC for up to 
several months, although it will very gradually degrade over this time.  
 
(iv) Use isolated RNA as template for reverse transcription with First Strand 
kit (Applied Biosystems) to produce cDNA for real-time qPCR analysis. 
Briefly, up to 1µg of RNA is used in a 50µl reaction, using random hexamers 
for cDNA synthesis: heat at 48ºC for 30 minutes, followed by 95ºC for 5 
minutes to terminate reaction.  
PAUSE POINT: At this stage, cDNA can be stored at -80ºC for several months 
until required.  
 
(v) Prepare PCR plate (BioRad) with SYBR green supermix (BioRad) and 
primer pairs used at 300nM (Sigma, custom-made), then add cDNA.  
 
(vi) Place in iCycler thermal cycler, with real-time PCR detection by MyIQ 
(both BioRad), then commence thermal cycle: 95ºC for 5 minutes, followed 
by 40 cycles of (95ºC for 15 seconds, 60ºC for 30 seconds, 72ºC for 30 
seconds with PCR detection) then carry out a melting curve and cool to 4ºC.  
PAUSE POINT: At this stage, PCR products can be stored at -20ºC for several 
months until required.  
 
(vii) Examine primer products sizes by electrophoresis to confirm specificity 
if required.  
 
TIMING 
 
Step 1A (i) takes ~25 minutes; steps 1A (ii)-(vi) take ~1 hour (assuming 
three hearts are processed); steps 1A (vii)-(xi) take ~25 minutes; steps 1A 
(xii)-(xvii) take ~2 hours. Total length of protocol from start to finish is ~4 
hours.  
 
Step 1B (i) takes ~25 minutes; steps 1B (ii)-(vii) take ~1 hour (assuming 
three hearts are processed, for one heart ~20 minutes); steps 1B (viii)-(xiv) 
take ~70 minutes; steps 1B (xv)-(xxi) take approximately 2 hours. Total 
length of protocol from start to finish is ~4.5 hours.  
 
The clonogenicity assay (step 2 option A) takes up to 9 days to complete. 
The generation of CardioStem Spheres (step 2 option B) requires up to 6 
days.  The cardiomyogenic differentiation of eCSCs in vitro (step 2 option C) 
requires up to 20 days (3 days oxytocin pre-treatment, ~3 days to grow 
CardioStem Spheres, 14 days of differentiation in defined stage-specific 
medium). The CytoSpin procedure (step 2 option D) takes ~35 minutes to 
complete. The chamber slide preparation procedure (step 2 option E) takes 
~7 days (to assay multipotency) or 20 days (for cardiomyogenic 
differentiation) to complete. The immunocytochemistry procedure (step 2 
option F) requires ~5 hours to complete working around an overnight 
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incubation for the primary antibody. Real-time qPCR analysis (step 2 option 
G) takes approximately 6 hours to complete.  
 
TROUBLESHOOTING 
 
A guide for troubleshooting problems encountered during this protocol is 
provided in Table 5.  
 
ANTICIPATED RESULTS 
 
Isolating c-kitpos eCSCs from the mouse heart 
 
Flow cytometric analysis of the c-kit and CD45 expression of cardiac small 
cells from the adult mouse heart demonstrates that in the unsorted cardiac 
small cell population  ~10% of small cells present in the adult mouse heart 
are c-kit-positive, CD45-positive (Figure 3a,b), and Tryp-positive. These 
cells are cardiac mast cells 6,33. Among the cardiac small cell population 
typically ~3% are c-kitpos CD45neg and Trypneg eCSCs (Figure 3b).  
To confirm the efficacy of the magnetic cell sorting system, we incubated 
sorted cells from step 1A (xii) with fluorochrome-conjugated antibodies and 
analysed them using flow cytometry. The removal of CD45-positive cells is 
completely effective, with the CD45-positive signal (labelled with 
fluorescein isothiocyanate, FITC) being removed entirely by negative 
selection of this cell population with magnetic activated cell sorting (Figure 
4a-c). Similarly, a strongly enriched population of cells for c-kit is provided 
by magnetic selection for this population (Figure 5a-c). By dual staining, 
~93% of cells are c-kitpos CD45neg following magnetic selection for these 
markers (Figure 5d,e). As the c-kitpos CD45neg eCSCs have been sorted using a 
PE-conjugated antibody, c-kit-unsorted cardiac small cells are used as a PE 
isotype control, as these cells have a comparable FSC/SSC distribution to 
the eCSC population (Supplementary Figure 1).  
 
Isolating c-kitpos eCSCs from the rat heart 
 
Flow cytometric analysis of c-kit and CD45 expression in cardiac small cells 
obtained at step 1B (xiv) from the adult rat heart demonstrates that in the 
unsorted cardiac small cell population, ~14% of the small cells present in the 
adult heart are c-kit-positive, CD45-positive (Figure 7a,b), and Tryp-
positive. These cells are cardiac mast cells (Figure 7c). Among the cardiac 
small cell population, typically ~4% are c-kitpos CD45neg Trypneg eCSCs (Figure 
7b).  
 
To confirm the efficacy of the magnetic cell sorting system, we incubated 
sorted cells with fluorochrome-conjugated antibodies and analysed using 
flow cytometry. As for the mouse, the removal of CD45-positive cells is 
effective, with the CD45-positive signal (labelled with FITC), being 83% in 
the positive selection, and 3% in the negative selection (Figure 8a-c). 
Similarly, a strongly enriched population of cells for c-kit is provided by 
magnetic selection for this population (Figure 9a-c). We note that the c-
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kitpos eCSC population expresses varying levels of c-kit (Figure 9c), which 
may reflect different levels of potency or the clipping of a fraction of c-kit 
by the proteolytic digestion step. The cause of this heterogeneity of 
detectable c-kit remains to be determined. By dual staining, ~86% of cells 
are c-kitpos CD45neg Trypneg following magnetic selection for these markers 
(Figure 9d,e), with complete absence of the mast cell marker tryptase 
(Figure 9f). 
 
Characterisation of eCSCs 
 
Flow cytometric analysis of freshly isolated c-kitpos CD45neg eCSCs for a panel 
of surface markers reveals a phenotype which is ~50% positive for Sca-1 and 
CD90 (Figure 10a,b); ~60% positive for CD105 and CD140a (PDGFrŞ) (Figure 
10c,d); ~65% positive for CD166 (Figure 10e); and negative for CD31 and 
CD34 (Figure 10f,g). 
 
The c-kitpos CD45neg eCSC populations derived from both mouse and rat adult 
hearts can be grown in culture beyond the population doubling limit of 
somatic cells (i.e. >40 passages over a period of months). Clonal populations 
of mouse and rat c-kitpos CD45neg eCSCs have a population doubling time of 
~15 hours (Figure 11a), and can be characterised by flow cytometry for 
appropriate eCSC surface marker expression (Figure 11b).  
 
The c-kitpos CD45neg eCSCs from the mouse and rat heart are self-renewing, 
maintaining stemness transcript expression over 30 consecutive culture 
passages (Figure 11c). Mouse and rat c-kitpos CD45neg eCSCs at passage 4 
have the ability to generate single cell-derived clonal colonies at a rate of 
~30% (Figure 11d), and also generate CardioStem Spheres when grown in 
suspension (Figure 11e).  
 
Depending on the cell types to be immunostained, either Cytospin 
preparations (for eCSCs) or chamber slides (for differentiated cells) are 
used. These methods allow successful immunocytochemical characterisation 
of c-kitpos CD45neg eCSCs (Figure 12a) and c-kitpos CD45neg eCSCs that have 
been differentiated into the 3 main cardiac lineages (Figure 12b-d; Figure 
13). The generation of the three lineages is achieved by generating 
CardioStem Spheres, which are then plated in laminin-coated chamber 
slides. CardioStem Spheres are similar to neurospheres 34 and cardiospheres 
14, with the difference that they are constituted of eCSCs instead of mixed 
small cells from the originating tissue. Once attached, cells from the 
CardioStem Spheres spontaneously differentiate into cells expressing 
markers of all 3 cardiac lineages; cardiomyocytes (Ş-sarcomeric actin: 
Figure 12b), smooth muscle (smooth muscle actin, SMA: Figure 12c) and 
endothelial (von Willebrand factor, vWF: Figure 12d) cells 2.  
 
This protocol can also be used to specify rat c-kitpos CD45neg eCSCs into 
functional, contracting cardiomyocytes in vitro. Oxytocin and specific 
growth factors governing embryonic cardiogenesis, given in a 
stage/sequence-specific manner (Figure 13a), produced contractile 
cardiomyocytes derived from cloned c-kitpos CD45neg eCSCs, as previously 
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shown 35. This CardioStem Sphere-beating assay is similar to the protocol 
used to assess cardiomyocyte differentiation in embryoid bodies 36. Cloned 
c-kitpos CD45neg eCSCs are treated with 100nM Oxytocin for 72 hours before 
transfer to bacteriological dishes for the generation of CardioStem Spheres 
(Figure 13a). Spheres grown in suspension are picked and plated in laminin-
coated chamber slides or dishes. Through trial and error we identified and 
demonstrated that supplementation of BMP-2, BMP-4, TGF-ş1 and Dkk-1 for 
4 days increased the number of cardiac troponin I expressing cells to ~40% 
(Figure 13b). However, with removal of TGF- ş1, BMP2, and BMP4 at day 4, 
and supplementing the medium with Dkk-1 for the remaining 10 days, the 
cardiomyocyte differentiation increased to ~70% cTnI positive cells (Figure 
13a,b). The cardiomyocyte cells exhibit abundant, well-organized sarcomere 
structures (Figure 13c) and functional synchronized rhythmic beating 
(Supplementary Video 1), which is stable and maintained for the duration of 
the culture. These cardiomyocytes behave like a syncytium connected 
through Cnx43-containing gap junctions (Figure 13c). A similar beating 
phenotype is exhibited by isolated cells when the sphere is disaggregated 
and cells individually plated (Supplementary Video 2). Real-time-qPCR of 
differentiated CardioStem Spheres at 14 days of culture in the 
cardiomyogenic cocktail showed a progressive decrease in transcripts for 
stemness and concomitant up-regulation of cardiomyocyte-specific 
transcription factors and genes coding for sarcomeric proteins (Figure 13d). 
This procedure was carried out using the primers and protocol as previously 
published by our group 4.  
 
The identification, isolation and propagation of a population of tissue-
specific stem cells resident in the adult heart open significant possibilities 
for a potential therapeutic option. Early trials of cardiac repair and 
regeneration via transplantation of bone marrow-derived stem/progenitor 
cells have given mixed and modest results (for review see 37), indicating that 
a better understanding of the relevant cell biology is required to provide a 
consistently effective therapeutic option for stem cell-based regenerative 
treatments in the heart. The presence of resident eCSCs in the adult heart, 
including human, has been determined by several groups 2,4,6,8-10,12,14,17,38-42. 
These cells can be isolated and propagated in vitro to produce large 
numbers of cells without reaching growth arrest or their being a change in 
cell characteristic. The cells are multipotent in vitro and in vivo 2,6,14. 
Therefore, these cells could be a source of a potential regenerative agent. 
The recent publication of the results of the SCIPIO and CADUCEUS trials 43,44 
provide further evidence of the potential therapeutic capabilities of these 
cells, demonstrating a therapeutic action of autologous eCSC infusion in 
patients following myocardial infarction. Another possible use for purified 
eCSCs is in drug test assays and to obtain patient-specific models of disease 
via cardiac progenitor cells derived from eCSCs in the manner achieved with 
human induced pluripotent stem cells 45. Thus this protocol enables the 
effective isolation and characterisation of the c-kitpos CD45neg eCSC 
population in the adult mouse and rat heart.  
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FIGURE LEGENDS 
 
Figure 1. Perfusion apparatus and system. (a) Perfusion apparatus and 
system. (b) Close-up of custom-made glass tubing.  
 
Figure 2. Diagrammatic representation of the steps of a mouse aorta 
cannulation procedure and heart hanging on the perfusion system. 
Diagrammatic representation of the steps of a mouse aorta cannulation 
procedure: (a) expose the heart and pass 5/0 suture thread behind the 
aorta, tying a very loose knot (b) grasp the right innominate artery with fine 
forceps (c) make a vertical cut into the bifurcation with Vannas scissors (d) 
advance the 19-gauge cannula into the opening (e) advance cannula 
carefully into aortic lumen, without passing through the aortic valve (f) tie 
suture thread with two knots, fixing the cannula in the aorta. (g) Heart 
hanging on the perfusion system (not yet perfused). (h) Perfused heart 
hanging on the system. These experiments were carried out in accordance 
with the regulations of the U.K. Home Office and the institutions regulatory 
boards.  
 
Figure 3. Flow cytometric analysis of unsorted mouse cardiac small cells. 
(a) Isotype control. (b) Cell population dual stained for CD45-FITC and c-kit-
PE, showing CD45 positive, c-kit negative cells (pink), c-kit positive, CD45 
positive cells (blue) and c-kit positive, CD45 negative eCSCs (green).  
 
Figure 4. Flow cytometric analysis of CD45 positive and negative sorted 
fractions shows mouse cardiac small cells are completely depleted of 
CD45-positive cells by magnetic sorting. (a) Isotype control. (b) Cell 
population negatively selected for CD45 and stained with CD45-FITC. (c) Cell 
population positively selected for CD45 and stained with CD45-FITC. 
Negative fluorescent signal is indicated by black, positive signal by red and 
the percentage of positively-labelled cells indicated.  
 
Figure 5. Flow cytometric analysis shows magnetic activated cell sorting 
of the CD45 negative selection for c-kit, yields a high purity of c-kitpos 
eCSCs from the mouse heart. (a) Isotype control. (b) Cell population 
negatively selected for c-kit, and stained with c-kit-PE. (c) Cell population 
positively selected for c-kit and stained with c-kit-PE. Negative fluorescent 
signal is indicated by black, positive signal by red. (d and e) Cell population 
dual stained for CD45-FITC and c-kit-PE, showing high purity of c-kitpos 
CD45neg eCSCs isolated from the mouse heart.  
 
Figure 6. Diagrammatic representation of the steps of a rat aorta 
cannulation procedure and the hearts hanging on the perfusion system. 
Diagrammatic representation of the steps of a rat aorta cannulation 
procedure: (a) advance the aorta around the cannula and hold in place with 
forceps, keeping the end of the cannula above the aortic valve (b) lower the 
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loosely-tied 4/0 suture thread over the aorta (c) tie the suture thread 
tightly in two knots, securing the aorta. (d) Three perfused hearts hanging 
on the perfusion system. These experiments were carried out in accordance 
with the regulations of the U.K. Home Office and the institutions regulatory 
boards. 
 
Figure 7. Analysis of unsorted rat cardiac small cells. (a, b) Flow 
cytometric analysis. (a) Isotype control. (b) Cell population dual stained for 
CD45-FITC and c-kit- AlexaFluor594, showing CD45 positive, c-kit negative 
cells (pink), c-kit positive, CD45 positive eCSCs (blue) and c-kit positive, 
CD45 negative eCSCs (green). (c) Immunocytochemical staining for tryptase 
positive in CD45-positive, c-kit-positive cells. Bar = 20µm.  
 
Figure 8. Flow cytometric analysis of CD45 positive and negative sorted 
fractions shows rat cardiac small cells are completely depleted of CD45-
positive cells by magnetic sorting. (a) Isotype control. (b) Cell population 
negatively selected for CD45 and stained with CD45-FITC. (c) Cell population 
positively selected for CD45 and stained with CD45-FITC. Negative 
fluorescent signal is indicated by black, positive signal by red and the 
percentage of positively-labelled cells indicated.  
 
Figure 9. Analysis shows magnetic activated cell sorting of the CD45 
negative selection for c-kit yields a high purity of c-kitpos eCSCs from the 
rat heart. (a-e) Flow cytometric analysis. (a) Isotype control. (b) Cell 
population negatively selected for c-kit, and stained with c-kit- 
AlexaFluor488. (c) Cell population positively selected for c-kit and stained 
with c-kit-AlexaFluor488. Negative fluorescent signal is indicated by black, 
positive signal by red. (d and e) Cell population dual stained for CD45-FITC 
and c-kit-AlexaFluor594, showing high purity of c-kitpos CD45neg eCSCs 
isolated from the rat heart. (f) Immunocytochemical staining for tryptase 
negative in CD45-negative, c-kit-positive cells. Bar = 20µm.  
 
Figure 10. Flow cytometric characterisation of freshly isolated c-kitpos 
CD45neg mouse eCSCs. Expression of Sca-1 (a), CD90 (b), CD105 (c), CD140a 
(d), CD166 (e), CD31 (f) and CD34 (g) on freshly isolated c-kitpos CD45neg 
eCSCs. (h) Isotype controls. Negative fluorescent signal is indicated by 
black, positive signal by red and the percentage of positively-labelled cells 
indicated.  
 
Figure 11. Isolated c-kitpos CD45neg eCSCs from both mouse and rat are 
clonogenic, self-renewing and form CardioStem Spheres. (a) Clonogenicity 
of c-kitpos eCSCs. Bar = 50µm. (b) Characterisation by flow cytometry of a 
single-cell derived c-kitpos CD45neg clonal population. (c) Population doubling 
time for clonal eCSCs. (d) Self-renewal as determined by the expression of 
stemness transcripts of clones over multiple passages. (e) CardioStem 
Sphere formation. Bar = 200µm. Data in each panel are Mean ± SD of 3 
independent experiments.  
 
Figure 12. Immunocytochemistry of c-kitpos CD45neg eCSCs and their 
multipotency. (a) Cytospin preparation and immunostained clonal c-kitpos 
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(green, c-kit; blue, DAPI) rat eCSCs. Clonal c-kitpos CardioStem Sphere cells 
are multipotent, differentiating into the 3 main cardiac lineages: (b) 
cardiomyocytes (red, alpha-sarcomeric actin; blue, DAPI), (c) smooth 
muscle cells (red, smooth muscle actin; blue, DAPI) and (d) endothelial cells 
(green, von Willebrand factor; blue, DAPI). Bars = 50µm.  
 
Figure 13. Differentiation of c-kitpos CD45neg eCSCs into functional 
beating cardiomyocytes in vitro. (a) Schematic timeline of the stage-
specific protocol used for the cardiomyogenic differentiation of c-kitpos 
CardioStem Spheres. (b) Frequency of cTnI-positive cells and percentage of 
beating cells (hatched bars) after manipulation of the TGF-ş/Wnt signalling 
pathways, determined by confocal microscopy and impartial observer 
counting, as indicated. *P<0.05 vs. all. (c) At days 8-14, CardioStem Sphere 
cells stain positive for the cardiomyocyte lineage (S-Actinin, green), 
exhibiting sarcomeric structures (z lines and dots) and gap junction 
formation (Cnx-43, red) between cells. Bar = 50m. (d) Real-time-qPCR 
analysis and PCR products following the stage-specific cardiomyocyte 
differentiation protocol, revealed the change in transcripts for c-kit, Tert, 
Nkx2.5, GATA-4, ş-MHC and cTnI in the differentiated CardioStem Sphere 
cells, relative to 0 days (undifferentiated cells). Data are Mean ± SD of 3 
assays.  
 
SUPPLEMENTARY FIGURES AND VIDEOS 
 
Supplementary Figure 1. Flow cytometric analysis: Forward scatter/side 
scatter gating. (a) Unsorted mouse cardiac small cells. (b) Mouse eCSCs. (c) 
Unsorted rat cardiac small cells. (d) Rat eCSCs.  
 
Supplementary Video 1. Cardiomyocyte cells exhibit functional 
synchronized rhythmic beating.  The cardiomyocyte cells derived from 
eCSCs exhibit functional synchronized rhythmic beating which is stable and 
maintained for the duration of the culture.  
 
Supplementary Video 2. Individual CardioStem Sphere-derived cells 
maintain rhythmic beating phenotype. Individually-plated cardiomyocyte 
cells derived from CardioStem Spheres following sphere disaggregation 
maintain a rhythmic beating phenotype in culture.  
 
TABLES 
 
Table 1. Summary of eCSC populations.  
Phenotype 
 
Markers Source 
c-kitpos eCSCs CD34neg, CD45neg, Sca-1pos, Abcg2pos, 
CD105pos, CD166pos, GATA4pos, 
NKX2-5pos/neg or low, MEF2Cpos 
Mouse, rat, dog, 
pig, human 
Sca-1pos eCSCs CD34neg, CD45neg, FLK1neg, ckitpos/neg 
or low, GATA4pos, NKX2-5pos/neg or low, 
MEF2Cpos 
Mouse, human 
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SP cells CD34pos, CD45pos, Abcg2pos, Sca1pos, 
c-kitpos, NKX2-5neg, GATA4neg 
Mouse 
Cardiosphere-derived cells CD105pos, CD34pos, CD45pos, 
Abcg2pos, Sca1pos, c-kitlow 
Mouse, rat, dog, 
pig, human 
cCFUFs Sca-1pos, PDGFRŞneg, CD31neg, c-
kitlow, CD45neg, FLK1neg, CD44pos, 
CD90pos, CD29pos, and CD105pos 
Mouse 
Cardiac mesangioblasts CD31pos, CD34pos, CD44pos, CD45neg, 
Sca1pos, c-kitpos 
Mouse, human 
Isl1pos CPCs CD31neg, Sca1neg, c-kitneg, GATA4pos, 
NKX2-5pos 
Mouse, rat, 
human 
 
Table 2. Summary of differences between mouse and rat eCSC isolation 
protocols.  
Stage Mouse Rat 
Cannulation 
(steps A (iii), B (iii)) 
 
Cannula inserted under 
microscope before heart 
removal from chest cavity 
Heart removed from chest 
cavity and aortic stump 
placed over cannula 
Perfusion 
(steps A (iv-vi), B (iv-vi)) 
 
Wash out blood with Basic 
Buffer; 10-12 minutes 
collagenase; 5 minutes 
BSA solution 
Wash out blood with K-H 
buffer; 15 minutes 
collagenase and 
hyaluronidase 
Tissue disaggregation 
(steps A (vii, viii), B (vii-
x)) 
 
Cut into ~1mm fragments 
and triturated in BSA 
solution 
Chopped into ~5mm 
fragments; digested for 
30-40 minutes 
Small cell separation 
(steps A (ix-xi), B (xi-
xiii)) 
 
Centrifuge: 300g/brake 3, 
1 minute;  
Pellet small cells: 
330g/brake 7, 7 minutes 
Centrifuge: 50g/brake 3, 
3 minutes;  
Pellet small cells: 
400g/brake 7, 7 minutes; 
Optiprep debris removal 
Magnetic eCSC isolation 
(steps A (xiii-xiv), B (xv-
xviii)) 
CD45 removal: OctoMACS
c-kit selection: EasySep 
CD45 removal: OctoMACS
c-kit selection: OctoMACS 
Anticipated cell yield 
(steps A (xv), B (xix)) 
~30,000 per mouse heart ~150,000 per rat heart
 
Table 3. Summary of antibody concentrations.  
Antibody Step Concentration
Anti-mouse CD45 MicroBeads (Miltenyi 130-
052-301) 
1A (xiii) 1µl/million cells 
(minimum 10µl) 
EasySep anti-mouse CD117 selection cocktail 
(Stem Cell Technologies 18757) 
1A (xiv) 0.5µl/million cells 
(minimum 5µl) 
Anti-mouse CD45-FITC conjugated (Miltenyi 
130-091-609) 
1A (xii, xv) 1µl/million cells 
(minimum 10µl) 
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Anti-mouse c-kit-PE conjugated (Stem Cell 
Technologies 18757C.1) 
1A (xii, xv) 1µl/million cells 
(minimum 10µl) 
Mouse IgG anti-rat CD45 antibody (Santa Cruz 
Biotechnology sc53047) 
1B (xv) 2µl/million cells 
(minimum 20µl) 
Mouse IgG anti-rat CD45-FITC conjugated 
antibody (Biolegend 202205) 
1B (xiv, xix) 1:200 
Rabbit IgG anti-rat c-kit antibody (Santa Cruz 
Biotechnology sc5535) 
1B (xvii)     
 
 
1B (xiv, xix)   
2µl/million cells 
(minimum 20µl) 
 
10µl/million cells 
(minimum 10µl) 
Rat anti-mouse IgG2a+b MicroBeads (Miltenyi 
130-047-201) 
1B (xvi) 2µl/million cells 
(minimum 20µl) 
Goat anti-rabbit IgG MicroBeads (Miltenyi 
130-048-602) 
1B (xviii) 2µl/million cells 
(minimum 20µl) 
Anti-mouse Sca-1-FITC conjugated antibody 
(Miltenyi 130-098-034) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD31-FITC conjugated antibody 
(Miltenyi 130-100-003) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD34-FITC conjugated antibody 
(BD 560238) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD90-PE conjugated antibody 
(Abcam Clone G7, ab24904) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD105-PE conjugated antibody 
(Miltenyi 130-098-018) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD140a-PE conjugated antibody 
(Miltenyi 130-096-271) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD166-PE conjugated antibody 
(eBioscience 12-1661-81) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD45-FITC conjugated antibody 
(Miltenyi 130-091-609) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Mouse IgG1 PE Isotype control (Abcam 
ab81200) 
1A (xii, xv)
 
10µl/million cells 
(minimum 10µl) 
Mouse IgG2a FITC Isotype control (Abcam 
ab81197)  
1A (xii, xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD117-PE conjugated antibody 
(Miltenyi 130-091-730) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-mouse CD45-PE conjugated antibody 
(Miltenyi 130-091-610) 
1A (xv)
 
10µl/million cells 
(minimum 10µl) 
Anti-tryptase antibody (Santa Cruz 
Biotechnology sc32473) 
2F (iii) 1:50 
Goat polyclonal anti-c-kit antibody (R and D 
systems AF1356) 
2F (iii) 1:50 
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Mouse IgM anti-Ş-sarcomeric actin antibody 
(Sigma A2127) 
2F (iii) 1:50 
Mouse IgG anti-smooth muscle actin antibody 
(Sigma A2547) 
2F (iii) 1:50 
Rabbit polyclonal anti-von Willebrand factor 
antibody (Dako A0082) 
2F (iii) 1:100 
Mouse monoclonal anti-Ş-actinin sarcomeric 
antibody (Sigma Clone EA-53, A7811) 
2F (iii) 1:50 
Rabbit polyclonal anti-Connexin 43 antibody 
(Sigma C6219) 
2F (iii) 1:50 
AlexaFluor 488 donkey anti-rabbit antibody 
(Jackson 711-545-152-JIR) 
1B (xix)
 
 
2F (v) 
10µl/million cells 
(minimum 10µl) 
 
1:100 
AlexaFluor 594 donkey anti-rabbit antibody 
(Jackson 711-585-152-JIR) 
1B (xiv, xix)
 
 
2F (v) 
10µl/million cells 
(minimum 10µl) 
 
1:100 
AlexaFluor 488 donkey anti-goat antibody 
(Jackson 705-545-147-JIR) 
2F (v) 1:100 
Alexa Fluor 488 donkey anti-mouse IgG 
antibody (Jackson 715-545-150-JIR) 
2F (v) 1:100 
AlexaFluor 594 donkey anti-mouse IgM 
antibody (Jackson 715-585-140-JIR) 
2F (v) 1:100 
AlexaFluor 594 donkey anti-mouse IgG 
antibody (Jackson 715-585-151-JIR) 
2F (v) 1:100 
 
Table 4. Summary of coating substrate volume, medium volume and cell 
plating density requirements for c-kit-positive, CD45-negative CSCs in 
culture (these apply to culture of either mouse or rat CSCs).  
Culture plate or dish Coating 
volume 
Medium 
volume 
Maximum cells at 
time of plating 
96-well plate 50µl 100-200µl 3,000
24-well plate 300µl 500-1000µl 10,000
4-well chamber slide 500µl 500µl 10,000
6-well plate/35mm dish 1ml 1.5ml 200,000
60mm dish 3ml 5ml 500,000
100mm dish 5ml 8ml n/a
25cm2 flask n/a 7ml n/a
75cm2 flask n/a 20ml n/a
 
Table 5. Troubleshooting guide.  
Stage Difficulty Action 
Cannulation 
(steps A (iii), B 
Difficulty inserting 
mouse cannula 
Ensure large enough hole cut in aorta 
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(iii)) 
 
 
Mouse aorta tearing 
when cannula 
inserted 
 
Heart falling off 
perfusion system 
Ensure aorta cut is vertical (diagonal cut 
increases risk of tearing innominate artery 
during cannula insertion) 
 
Ensure aorta well tied on to cannula; ensure 
cannula sufficiently advanced into aorta 
Perfusion 
(steps A (iv, v), 
B (iv)) 
 
 
Poor perfusion
 
 
 
 
 
 
 
 
 
 
 
 
Residual blood in 
ventricles 
 
Over-digestion 
 
Likely cause is clotting due to delay in 
commencing perfusion: optimise technique to 
minimise sacrifice to perfusion time 
 
Over-insertion of cannula: for mouse, should 
stop advancing cannula when resistance (due to 
aortic valve leaflets) is felt and retract it 1mm 
back to ensure avoidance of obstructing 
coronary arteries ostium; for rat, can retract 
cannula up the aorta a very short distance to 
prevent the cannula tip covering coronary 
artery apertures 
 
Possibly due to poor perfusion generally as 
described above 
 
Pierce ventricular apex with 25-gauge needle 
(for mouse) or 18-gauge needle (for rat); for 
rat, can use forceps to dislodge blood (as 
described in step B (v)) 
Tissue 
disaggregation 
(step A (vii, 
viii), B (vii-x)) 
 
Poor disaggregation
 
 
 
 
 
Few cells intact 
 
 
 
 
 
Few cardiomyocytes 
intact 
Likely due to under-digestion secondary to poor 
perfusion (see above) 
 
May be due to tissue being inadequately cut 
(steps A (vii), B (vii)) 
 
Over-digestion of tissue (check enzyme activity 
levels) 
 
Insufficiently rapid perfusion of heart following 
sacrifice 
 
Over-digestion of tissue (check enzyme activity 
levels) 
 
Insufficiently rapid perfusion of heart following 
sacrifice 
CD45 removal 
(step A (xiii), B 
(xv-xvi)) 
 
 
Poor selection purity
 
 
 
 
 
 
 
Ensure that small cell preparation is not 
contaminated by cardiomyocytes or too much 
cardiomyocyte debris 
 
Ensure column is not overloaded with cells 
(check columns maximum capacity) and that 
pre-separation filter is in place 
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Few remaining cells 
 
Inadequate labelling with MicroBeads: check lot 
and that correct concentration of MicroBeads 
used for cell number 
 
Ensure column is not overloaded with cells 
(unlabelled cells may be trapped in the packed 
column) 
c-kit selection 
(step A (xiv), B 
(xvii-xviii)) 
 
Poor selection purity
 
 
 
 
 
 
 
 
 
 
 
Few selected cells 
 
Ensure that small cell preparation is not 
contaminated by cardiomyocytes or too many 
cardiomyocyte debris 
 
Ensure column is not overloaded with cells 
(check columns maximum capacity) and that 
pre-separation filter is in place 
 
Ensure column is not overloaded with cells 
(unlabelled cells may be trapped in the packed 
column) 
 
Inadequate labelling with MicroBeads or 
labelling cocktail: check lot and that correct 
concentration of reagent(s) used for cell 
number 
 
The c-kit receptor is very sensitive to digestive 
enzymes: ensure the tissue has not been over-
digested 
Culture of 
eCSCs 
(step A (xvi-
xvii), B (xx-xxi)) 
 
Cells not adhering or 
surviving 
 
 
 
 
Cells not proliferating 
 
 
 
 
 
 
 
 
 
Cells not maintaining 
stem-ness 
 
Plate coating (1.5% gelatin) assists freshly-
plated eCSCs adherence and survival 
 
Ensure time to perfusion and degree of 
digestion optimal 
 
Ensure eCSCs are plated at optimal levels: 
overly sparse plating is associated with slower 
eCSC proliferation. The eCSCs should be 
passaged approximately 1:4, adjusted as 
necessary  
 
Confirm growth medium made as per protocol, 
including L-glutamine supplementation of 
Neurobasal medium 
 
Check lot of ESQ serum: batch test if necessary 
 
Confirm eCSC phenotype 
 
Ensure eCSCs do not become over-confluent, as 
this can lead to differentiation (passage eCSCs 
on reaching 80% confluency) 
Cardiomyocyte 
differentiation 
Cells not 
differentiating 
Check phenotype of cells (confirm eCSC 
phenotype) 
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(step 2B)  
Cells not beating 
 
Ensure all growth factors effective and that 
medium is replenished as required 
CytoSpin ICC 
(step 2D) 
Cell morphology 
abnormal 
Ensure appropriate CytoSpin speed and 
acceleration 
 
Ensure appropriate fixative/duration of fixation 
used (as per protocol) 
Chamber slide 
ICC 
(step 2E) 
Cell morphology 
abnormal 
 
 
Ensure medium meniscus is not too low 
 
Ensure surface coating covers all of growth 
surface during pre-plating preparation 
 
 
 













